Go Pro
NASDAQ:SRZN

Surrozen Q1 2026 Earnings Report

Surrozen logo
$24.02 +0.25 (+1.03%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Surrozen EPS Results

Actual EPS
-$11.65
Consensus EPS
-$1.09
Beat/Miss
Missed by -$10.56
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
$5.00 million
Expected Revenue
$4.00 million
Beat/Miss
Beat by +$1.00 million
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 6, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Surrozen's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surrozen Earnings Headlines

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?
HC Wainwright Reaffirms Buy Rating for Surrozen (NASDAQ:SRZN)
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.tc pixel
Surrozen Inc
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN) is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. Surrozen’s pipeline spans both preclinical and clinical stages and includes programs addressing ocular surface disease, gastrointestinal disorders and solid tumors—indications characterized by impaired tissue healing or dysregulated Wnt activity.

To advance its pipeline, Surrozen has entered into strategic collaborations and research agreements with academic institutions and biopharmaceutical partners. These alliances are aimed at validating novel Wnt targets, enhancing antibody design and accelerating the translation of lead candidates into clinical development. The company is actively preparing multiple investigational new drug applications and expects to initiate additional clinical trials in the near term.

Surrozen is led by President and Chief Executive Officer Laura Shawver, PhD, supported by a management team with deep expertise in antibody engineering, developmental biology and translational medicine. The company’s research and development operations are based in the San Francisco Bay Area, where it maintains dedicated laboratory and manufacturing facilities to support its growing pipeline.

View Surrozen Profile